Covalon Technologies Ltd. (OTCMKTS:CVALF - Get Free Report) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 3,200 shares, a drop of 67.3% from the January 31st total of 9,800 shares. Based on an average trading volume of 26,800 shares, the days-to-cover ratio is currently 0.1 days.
Covalon Technologies Trading Down 3.2 %
Shares of CVALF traded down $0.06 on Tuesday, reaching $1.73. 200 shares of the company's stock traded hands, compared to its average volume of 21,912. The stock has a market cap of $47.35 million, a PE ratio of 24.67 and a beta of -0.29. The stock's 50 day simple moving average is $2.15 and its two-hundred day simple moving average is $2.33. Covalon Technologies has a 52-week low of $0.74 and a 52-week high of $3.08.
Covalon Technologies (OTCMKTS:CVALF - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.06. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $6.37 million. Covalon Technologies had a return on equity of 12.33% and a net margin of 8.58%.
About Covalon Technologies
(
Get Free Report)
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.
Featured Stories
Before you consider Covalon Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Covalon Technologies wasn't on the list.
While Covalon Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
